Company news
Patrys Limited (ASX:PAB) news
Patrys Limited news releases on 6ix. Latest, Oct 5, 2026: Investor Webinar
Press releases & updates
Investor Webinar
October 5, 2026
Appendix 4E Variance Report
September 28, 2026
First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
September 22, 2026
PAB Establishes Clinical Advisory Committee
September 16, 2026
Ethics Approval Secured for Phase 1A Clinical Trial
August 27, 2026
Investor Presentation - TechKnow Invest Roadshow
July 26, 2026
Appendix 4C - Quarterly - 30 June 2026
July 21, 2026
Patrys Secures 50% Revenue Share in IP Commercialisation
July 12, 2026
Patrys advances RLS-2202 toward Phase 1 Clinical Trial
May 19, 2026
Appendix 4C - Quarterly - 31 March 2026
April 29, 2026
$3.2 million Placement to Advance Clinical Trials
April 19, 2026
Investor Presentation - Broker Meets Biotech
March 30, 2026
RLS-2201 Manufacturing and Regulatory Pathway Initiated
March 10, 2026
Appendix 4D - Half Year Accounts - 31 December 2025
February 26, 2026
Appointment of Chief Executive Officer
February 11, 2026
Appendix 4C - Quarterly - 31 December 2025
January 29, 2026
Investor Presentation
January 27, 2026
Completion of Acquisition and Board Appointments
January 27, 2026
Pipeline Expanded with Proprietary Injectable Antipsychotic
November 25, 2025
Trading Halt
November 23, 2025
Appendix 4C - Quarterly - 30 September 2025
October 29, 2025
Patrys Receives R&D Tax Incentive Refund
October 29, 2025
Notice of Annual General Meeting/Proxy Form
September 7, 2025
Appendix 4E - Preliminary Final Report
August 29, 2025
Appendix 4C - Quarterly - 30 June 2025
July 29, 2025
Entitlement Offer Prospectus
July 23, 2025
Non-Renounceable Entitlement Offer
July 23, 2025
Deed of Release entered into with CEO
June 16, 2025
Successful Placement and Board Changes
June 10, 2025
Reinstatement to Official Quotation
June 10, 2025
Suspension from Quotation
June 3, 2025
Appendix 4C - Quarterly - 31 March 2025
April 30, 2025
Appendix 4D - Half Year Accounts - 31 December 2024
February 21, 2025
Appendix 4C - Quarterly - 31 December 2024
January 29, 2025
Appendix 4C - Quarterly - 30 September 2024
October 29, 2024
PAT-DX1 clinical development update
October 1, 2024
PAT-DX1 GMP specification testing update
September 19, 2024
Appendix 4E and 2024 Annual Report
August 23, 2024
Further update on PAT-DX1 GMP manufacturing run
July 28, 2024
Appendix 4C - Quarterly - 30 June 2024
July 23, 2024
Update on GMP manufacturing run of PAT-DX1
June 30, 2024
Appendix 4C - Quarterly - 31 March 2024
April 29, 2024
Positive preclinical data for deoxymabs in vasculitis
April 8, 2024
Appendix 4D - Half Year Accounts - 31 December 2023
February 23, 2024
Appendix 4C - Quarterly - 31 December 2023
January 22, 2024
GMP Production of PAT-DX1 Next Quarter
December 12, 2023
Appendix 4C - Quarterly - 30 September 2023
October 19, 2023
Appendix 4E and 2023 Annual Report
August 28, 2023
Appendix 4C - Quarterly - 30 June 2023
July 25, 2023
PAT-DX1 GLP toxicology reports received
May 23, 2023